Table 1

Background and clinical characteristics

CharacteristicsTotal
N=3191 (%)
Death
n=344 (%)
Others
n=2847 (%)
Mortality rate per 100 person years at risk (95% CI)
Gender
 Male1986 (62.2)244 (70.9)1742 (61.2)4.0 (3.4 to 4.5)
 Female1205 (37.8)100 (29.1)1105 (38.8)2.4 (1.9 to 3.9)
Ethnicity
 Non-indigenous1396 (43.7)143 (41.6)1253 (44)3.2 (2.6 to 3.8)
 Indigenous1795 (56.3)201 (58.4)1594 (56)3.5 (3.0 to 4.1)
Age at ART initiation, median (IQR)36 (32–42)37 (32–43)36 (32–42)
 ≤36 years1597 (50)170 (49.4)1427 (50.1)3.6 (3.1 to 4.2)
 >36 years1594 (50)174 (50.6)1420 (49.9)3.1 (2.7 to 3.7)
Residence
 Valley916 (28.7)122 (35.5)794 (27.9)3.1 (2.5 to 3.7)
 Hill1280 (40.1)126 (36.6)1154 (40.5)3.2 (2.6 to 3.8)
 Terai995 (31.2)96 (27.9)899 (31.6)4.2 (3.3 to 5.3)
Clinical stage
 Stage I750 (23.5)42 (12.2)708 (24.9)1.8 (1.3 to 2.5)
 Stage II845 (26.5)39 (11.3)806 (28.3)1.3 (0.9 to 1.9)
 Stage III1086 (34.0)123 (35.8)963 (33.8)3.7 (3.1 to 4.5)
 Stage IV510 (16.0)140 (40.7)370 (13)10.2 (8.4 to 12.3)
CD4 cell count (cells/cm3),* median (IQR)132 (64–201)85 (41–140)139 (70–208)
 ≤50523 (18.4)91 (28.7)432 (17.1)6.0 (4.7 to 7.5)
 51–100570 (20.0)93 (29.3)477 (18.9)5.2 (4.1 to 6.6)
 101–2001033 (36.3)103 (32.5)930 (36.8)2.8 (2.2 to 3.4)
 >200721 (25.3)30 (9.5)691 (27.3)1.1 (0.8 to 1.7)
Duration of ART initiation, median (IQR)21 (1–54)3 (1–13.2)24 (2–58)
 ≤3 months956 (30)184 (53.5)772 (27.1)311.9 (261.6 to 372.0)
 >3–6 months174 (5.5)40 (11.6)134 (4.7)55.9 (41.0 to 76.2)
 >6–12 months239 (7.5)30 (8.7)209 (7.3)16.2 (11.3 to 23.1)
 >12–24 months395 (12.4)36 (10.5)359 (12.6)5.6 (4.0 to 7.8)
 >24 months1427 (44.7)54 (15.7)1373 (48.2)0.7 (0.5 to 0.9)
  • *Missing, overall cohort period: 8484.8 person years; mortality rate per 100 person years (95% CI) 3.3 (3.0 to 3.7). P value obtained from χ2 test for categorical variables and Wilcoxon signed-rank for continuous variables.

  • ART, antiretroviral therapy.